NGAL is a precocious marker of therapeutic response.
(2011) Current Pharmaceutical Design — Vol. 17, n° 8, p. 844-849 (2011)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- NGAL (Neutrophil Gelatinase-Associated Lipocalin) is a small 25-kD peptide belonging to the lipocalin superfamily. Several studies highlight its role as an organ injury and disease activity biomarker. In the present review, instead, we wanted to study NGAL as a precocious marker of therapeutic response in renal and non-renal diseases (glomerulonephritis, vasculitis, LES, Crohn's disease and other chronic inflammatory pathologies). The obtained outcomes support the hypothesis that NGAL could be employed as a biomarker of response to different therapeutic schemes, because its levels sensibly and precociously change compared to other haematologic and biochemical parameters.
- Affiliations
Citations
Cernaro, V., Bolignano, D., Donato, V., Lacquaniti, A., Buemi, A., Crascì, E., Lucisano, S., & Buemi, M. (2011). NGAL is a precocious marker of therapeutic response. Current Pharmaceutical Design, 17(8), 844-849. https://doi.org/10.2174/138161211795428939 (Original work published 2011)